Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.67 |
| ▸ | GBA1 | P04062 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16678919 | 0.94 | SLC2A1 (0.58) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL12947359 | 0.93 | SLC2A1 (0.61) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL28066824 | 0.92 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL28069563 | 0.92 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL28066817 | 0.92 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL28069583 | 0.92 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL27938366 | 0.92 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL9332917 | 0.92 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL2361480 | 0.92 | SLC2A1 (0.56) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL16678933 | 0.92 | SLC2A1 (0.56) | SLC2A1GBA1MAPK1GJB2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2005105988-A2 | CRYSTAL STRUCTURE OF HUMAN JAK3 KINASE DOMAIN COMPLEX AND BINDING POCKETS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-0377349-B1 | Recombinant polypeptides of the haemorrhagical septicemia virus in fish | EUROGENTEC SA (BE) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008340-B2 | Modulators of ROR-gamma | RORC, RORB, RORA | SLC2A1 3792/4885GBA1 2373/4885MAPK1 1515/4885 |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | SLC2A1 3792/4885GBA1 2373/4885MAPK1 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.